within Pharmacolibrary.Drugs.N_NervousSystem.N02B_OtherAnalgesicsAndAntipyretics.N02BG09_Methoxyflurane;

model Methoxyflurane
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C(
    weight = 70,
    F = 1,
    Cl = 8.866666666666666e-05,
    adminDuration = 600,
    adminMass = 3 / 1000000,
    adminCount = 1,
    Vd = 0.0014,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    Vdp = 0.0025,
    k12 = 0.00010499999999999999,
    k21 = 0.00010499999999999999);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Methoxyflurane</td></tr><tr><td>ATC code:</td><td>N02BG09</td></tr><td>route:</td><td>inhalation</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>3</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>1.4</td><td>L</td></tr>
    <tr><td>clearance:</td><td>0.076</td><td>L/min/kg</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Methoxyflurane is a volatile inhalational anesthetic and analgesic agent historically used for general anesthesia. Due to concerns about nephrotoxicity, its use as an anesthetic has declined, but it is still used at lower doses for short-term pain relief, particularly in emergency settings and some countries as an inhaled analgesic for acute trauma pain.</p><h4>Pharmacokinetics</h4><p>Healthy adult volunteers, inhaled administration, single low-dose for analgesia.</p><h4>References</h4><ol><li><p>Kubica, A, et al., &amp; Kubica, J (2021). ANalgesic Efficacy and safety of MOrphiNe versus methoxyflurane in patients with acute myocardial infarction: the rationale and design of the ANEMON-SIRIO 3 study: a multicentre, open-label, phase II, randomised clinical trial. <i>BMJ open</i> 11(3) e043330–None. DOI:<a href=\"https://doi.org/10.1136/bmjopen-2020-043330\">10.1136/bmjopen-2020-043330</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33649058/\">https://pubmed.ncbi.nlm.nih.gov/33649058</a></p></li><li><p>Dudziak, R, &amp; Vettermann, J (1996). [Uptaken distribution and metabolism of sevoflurane]. <i>Der Anaesthesist</i> 45 Suppl 1 S1–S9. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/8775096/\">https://pubmed.ncbi.nlm.nih.gov/8775096</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.N.N02BG09 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Methoxyflurane;
